SEC Form 4 · accession 0000899243-19-002142
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Horgan
Officer — Chief Medical Officer and EVP
Period of report
Jan 25, 2019
Accepted (ET)
Jan 29, 2019 · 6:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)F1 | $6.01 | Jan 25, 2019 | A | 30,000 | A | — | Jan 24, 2029 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.